Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR Study

Jeremy Cole, Gene Colice(AstraZeneca (Spain))
Pulmonary Therapy
December 8, 2023
10.1007/s41030-023-00245-9
Cited by 3

Related Papers

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
|New England Journal of Medicine|2023|452
An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyl-L-arginine hydrochloride (546C88), in patients with septic shock
|Critical Care Medicine|1999|200